Table 2 Cancer type and stage of patients receiving cisplatin based chemotherapy
Site of cancer | Stage of tumor (N = 200) | Total (%) | ||
|---|---|---|---|---|
Early (%) | Locally advanced (%) | Metastatic (%) | ||
Lung | 1 (0.5) | 16 (8) | 21 (10.5) | 38 (19) |
Gastric/GEJ | 2 (1) | 8 (4) | 10 (5) | 20 (10) |
Head and Neck | 1 (0.5) | 14 (7) | 19 (9.5) | 34 (17) |
Pancreatic | 0 | 4 (2) | 9 (4.5) | 13 (6.5) |
Ovarian | 1 (0.5) | 5 (2.5) | 0 | 6 (3) |
Esophageal | 1 (0.5) | 6 (3) | 9 (4.5) | 16 (8) |
Germ Cell | 3 (1.5) | 1 (0.5) | 9 (4.5) | 13 (6.5) |
Cervical/Vulvar | 0 | 3 (1.5) | 7 (3.5) | 10 (5) |
Bladder | 0 | 5 (2.5) | 7 (3.5) | 12 (6) |
Endometrial | 1 (0.5) | 3 (1.5) | 0 | 4 (2) |
Chloangiocarcinoma | 0 | 2 (1) | 2 (1) | 4 (2) |
Breast | 0 | 3 (1.5) | 3 (1.5) | 6 (3) |
Carcinoma of unknown primary (CUP) | 0 | 6 (3) | 2 (1) | 8 (4) |
Gall bladder/peri-ampullary | 0 | 4 (2) | 3 (1.5) | 7 (3.5) |
Lymphomaa | 0 | 9 (4.5) | 9 (4.5) | |